Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: abro e. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Keane C, Law SC, Gould C, Birch S, Sabdia MB, Merida de Long L, Thillaiyampalam G, Abro E, Tobin JW, Tan X, Xu-Monette ZY, Young KH, Gifford G, Gabreilli S, Stevenson WS, Gill A, Talaulikar D, Jain S, Hernandez A, Halliday SJ, Bird R, Cross D, Hertzberg M, Gandhi MK. Keane C, et al. Among authors: abro e. Blood Adv. 2020 Apr 14;4(7):1367-1377. doi: 10.1182/bloodadvances.2019001390. Blood Adv. 2020. PMID: 32267932 Free PMC article.
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Tiong IS, Dillon R, Ivey A, Kuzich JA, Thiagarajah N, Sharplin KM, Kok CH, Tedjaseputra A, Rowland JP, Grove CS, Abro E, Shortt J, Hiwase DK, Bajel A, Potter NE, Smith ML, Hemmaway CJ, Thomas A, Gilkes AF, Russell NH, Wei AH. Tiong IS, et al. Among authors: abro e. Blood Adv. 2021 Dec 14;5(23):5107-5111. doi: 10.1182/bloodadvances.2021005455. Blood Adv. 2021. PMID: 34555849 Free PMC article.
Gemcitabine-induced thrombotic microangiopathy.
Richmond J, Gilbar P, Abro E. Richmond J, et al. Among authors: abro e. Intern Med J. 2013 Nov;43(11):1240-2. doi: 10.1111/imj.12261. Intern Med J. 2013. PMID: 24237646
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, Reynolds J, Anstee N, Nguyen T, Loo S, Chua CC, Ashby M, Wiltshire KM, Fleming S, Fong CY, Teh TC, Blombery P, Dillon R, Ivey A, Wei AH. Tiong IS, et al. Among authors: abro e. J Clin Oncol. 2024 Jun 20;42(18):2161-2173. doi: 10.1200/JCO.23.01599. Epub 2024 Mar 1. J Clin Oncol. 2024. PMID: 38427924 Free PMC article. Clinical Trial.